Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy

被引:20
作者
Loeb, Stacy [1 ]
Roehl, Kimberly A. [2 ]
Vipraleasit, Davis P. [3 ]
Catalona, William J. [3 ]
机构
[1] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21205 USA
[2] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63130 USA
[3] NW Feinberg Sch Med, Dept Urol, Chicago, IL USA
关键词
adjuvant radiation; progression; prostate cancer; radical prostatectomy; salvage radiation;
D O I
10.1016/j.eururo.2008.03.066
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Randomized trials have shown an improvement in progression-free survival rates with adjuvant radiation therapy (ART) after radical prostatectomy for patients with a high risk of cancer recurrence. Less is known about the relative advantages and disadvantages of initial observation with delayed salvage radiation therapy (SRT). Objective: To examine the results of SRT in a large single-surgeon radical prostatectomy series. Design, Setting, and Participants: From a radical prostatectomy database, we identified 859 men with positive surgical margins (SM+), extracapsular tumor extension (ECE), or seminal vesicle invasion (SVI) who chose to defer ART. Following a period of initial observation, 192 ultimately received SRT for prostate-specific antigen (PSA) progression. Measurements: Survival analysis was performed to examine the outcomes of initial observation followed by SRT. Results and Limitations: in patients with SM+/ECE and SVI, the 7-yr PSA progression-free survival rates with observation were 62% and 32%, respectively. Among those who had PSA progression, 56% and 26%, respectively, maintained an undetectable PSA for 5 yr after SRT. The long-term rates of undetectable PSA associated with an SRT strategy were 83% and 50% for men with SM+/ECE and SVI, respectively. In the subset of 716 men who did not receive any hormonal therapy, the corresponding long-term rates of undetectable PSA were 91% and 75%, respectively. Conclusions: Following radical prostatectomy, initial observation followed by delayed SRT at the time of PSA recurrence is an effective strategy for selected patients with SM+/ECE. Some patients with SVI may also benefit from this strategy. However, additional prospective studies are necessary to further examine the survival outcomes following SRT. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 96
页数:9
相关论文
共 21 条
[1]
Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[2]
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma [J].
Cheng, L ;
Jones, TD ;
Lin, HQ ;
Eble, JN ;
Zeng, G ;
Carr, MD ;
Koch, MO .
JOURNAL OF UROLOGY, 2005, 174 (06) :2181-2185
[3]
Patients at high risk of progression after radical prostatectomy:: Do they all benefit from immediate post-operative irradiation?: (EORTC trial 22911) [J].
Collette, L ;
van Poppel, H ;
Bolla, M ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
Piérart, M .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (17) :2662-2672
[4]
Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Schultz, D ;
Loffredo, M ;
Dugal, R ;
Hurwitz, M ;
Kaplan, I ;
Beard, CJ ;
Renshaw, AA ;
Kantoff, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10) :1280-1283
[5]
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135
[6]
Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study [J].
Gontero, Paolo ;
Marchioro, Giansilvio ;
Pisani, Roberta ;
Zaramella, Stefano ;
Sogni, Filippo ;
Kocjancic, Ervin ;
Mondaini, Nicola ;
Bonvini, Daniele ;
Tizzani, Alessandro ;
Frea, Bruno .
EUROPEAN UROLOGY, 2007, 51 (04) :922-930
[7]
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy - The 15-year Johns Hopkins experience [J].
Han, M ;
Partin, AW ;
Pound, CR ;
Epstein, JI ;
Walsh, PC .
UROLOGIC CLINICS OF NORTH AMERICA, 2001, 28 (03) :555-+
[8]
Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis [J].
Harnden, Patricia ;
Shelley, Mike D. ;
Coles, Bernadette ;
Staffurth, John ;
Mason, Malcom D. .
LANCET ONCOLOGY, 2007, 8 (05) :411-419
[9]
Cancer control with radical prostatectomy alone in 1,000 consecutive patients [J].
Hull, GW ;
Rabbani, F ;
Abbas, F ;
Wheeler, TM ;
Kattan, MW ;
Scardino, PT .
JOURNAL OF UROLOGY, 2002, 167 (02) :528-534
[10]
Prognostic impact of positive surgical margins in surgically treated prostate cancer:: Multi-institutional assessment of 5831 patients [J].
Karakiewicz, PI ;
Eastham, JA ;
Graefen, M ;
Cagiannos, I ;
Stricker, PD ;
Klein, E ;
Cangiano, T ;
Schröder, FH ;
Scardino, PT ;
Kattan, MW .
UROLOGY, 2005, 66 (06) :1245-1250